The demo reached equally its Key endpoints, with semaglutide 2.4 mg demonstrating statistically major and outstanding improvements in liver fibrosis without worsening of steatohepatitis, and also resolution of steatohepatitis without worsening of liver fibrosis in people with MASH when compared to p